In a recent publication by Risch and colleagues (1), regular use of aspirin was associated with reduced risk of pancreatic cancer (1). Few options besides the avoidance of smoking and obesity are available to prevent pancreatic cancer (1). It has been highlighted that people who take aspirin for prevention of other diseases, including cardiovascular disease, likely also reduce their risk of developing pancreatic cancer (1). Aspirin has been established more than a quarter century ago as an evidence-based therapy to reduce recurrent cardiovascular events in patients affected by coronary artery disease based on limited data by contemporary standards (2). However, aspirin for secondary prevention in patients suffering from ischemic heart disease has been recently and critically reappraised (2). The anticancer effects of aspirin have been indicated in a variety of organs, although the precise mechanisms remain unknown (...

You do not currently have access to this content.